Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

<keyword id="19910149" type="General" weightage="100" keywordseo="AstraZeneca" source="keywords" meta.keywordsubtype="org" meta.entityname="AstraZeneca" meta.hostid="261" meta.entityid="AstraZeneca">AstraZeneca</keyword> made headlines on Tuesday as it initiated the global withdrawal of its COVID-19 vaccine. This decision comes weeks after the pharmaceutical giant acknowledged the vaccine's potential to trigger a rare side effect known as <keyword id="21475609" type="General" weightage="20" keywordseo="Thrombosis-with-Thrombocytopenia-Syndrome" source="keywords">Thrombosis with Thrombocytopenia Syndrome</keyword> (TTS). Previously, AstraZeneca had admitted in court filings that its vaccine could lead to side effects like <keyword id="21303970" type="General" weightage="20" keywordseo="blood-clots" source="keywords">blood clots</keyword> and low blood platelet counts. However, the company has now attributed its <keyword id="21572759" type="General" weightage="20" keywordseo="vaccine-withdrawal" source="Orion">vaccine withdrawal</keyword> not to the aforementioned side effects, but to an "oversupply of updated vaccines" since the pandemic. The company also announced its decision to revoke the vaccine Vaxzevria's marketing authorisations within Europe, noting that the oversupply has reduced the demand for Vaxzevria, which is no longer being produced or distributed. According to The Telegraph, AstraZeneca had submitted its application to withdraw the vaccine on March 5, and the withdrawal became effective on May 7. AstraZeneca collaborated with the University of Oxford to develop the Vaxzevria vaccine, while also partnering with the <keyword id="19897707" type="General" weightage="20" keywordseo="Serum-Institute-of-India" source="keywords" meta.keywordsubtype="org" meta.entityname="Serum Institute of India" meta.hostid="261" meta.entityid="Serum Institute of India">Serum Institute of India</keyword> (SII), the world's largest vaccine manufacturer, to supply the Covishield vaccine to the Indian government. The UK-based pharma company is currently facing <keyword id="19982808" type="General" weightage="20" keywordseo="legal-action" source="keywords">legal action</keyword> alleging that its vaccine has caused deaths and severe harm to a few of those who received it. <cmsannotation type="cmsannotation" annotationid="The lawsuits against AstraZeneca" comment="subhead" text="The lawsuits against AstraZeneca">The lawsuits against AstraZeneca</cmsannotation> Families of individuals affected by adverse vaccine reactions continue to pursue legal recourse against AstraZeneca and the Serum Institute of India. <keyword id="21513237" type="General" weightage="20" keywordseo="venugopalan-govindan" source="keywords">Venugopalan Govindan</keyword>, whose daughter Karunya passed away after receiving the Covishield vaccine, expressed his grief and criticised various parties for his daughter's death. He highlighted alleged negligence in responding to early warning signs and cited missed opportunities to prevent tragedies like his daughter's passing. Eight families across India have joined forces to seek justice, emphasising their collective determination to hold accountable those they deem responsible for the tragic loss of their loved ones. Their shared resolve underscores their commitment to achieving justice and preventing similar tragedies from occurring again, he added. In the UK, <keyword id="21472612" type="General" weightage="20" keywordseo="jamie-scott" source="keywords">Jamie Scott</keyword> took legal action last year after suffering from a blood clot and brain bleed following his vaccination in April 2021. AstraZeneca initially denied a causal link between the vaccine and this particular side-effect, but later admitted in court documents that the vaccine could cause TTS in very rare cases. As many as 51 cases have reportedly been filed against AstraZeneca in the British High Court, with affected individuals and families seeking compensation totaling an estimated £100 million. (With inputs from multiple agencies)

AstraZeneca continues to face legal action even after withdrawing its COVID vaccine! Know all about it here

<ul class="summary-list"><li>Ariel Sophia Bardi was dealing with grief and was unhappy with her desk job.</li><li>When the opportunity to travel to Algeria for her 40th birthday came up, she jumped at the chance. </li></ul>I was chest-deep in bathwater, listening to the sound of soapy foam popping. I'd timed the moment so that when the clock struck midnight — and <a target="_blank" class="" href="https://www.businessinsider.com/altitude-psychosis-hiking-hallucinations-mountain-climbing-rules-to-follow-avoid-2024-8">I turned 40</a> — I'd be soaking in a bubble bath on the coast of <a target="_blank" class="" href="https://www.businessinsider.com/how-travel-full-time-make-money-social-media-2023-9">Algeria</a>. I needed an elegant backdrop as I stared my future in the face.I'd splurged on a single night in a sprawling hilltop estate with arches and colorful tiles. Palms rustled outside my window, and lights twinkled over the Bay of Algiers. The hotel had been constructed in a Moorish revival style at the end of the 19th century. I was used to more spartan sleeping arrangements, having spent much of my 30s as a freelance journalist. For the past several years, I'd been working a desk job and on autopilot. It started at some point during those mushy, airless pandemic years. A therapist would pinpoint my numbness to when my dad's heart suddenly stopped, in 2020. <h2 id="05278691-3b1e-4411-acea-ab3d0c3145d6">Dealing with grief while working a desk job</h2>In those Covid-averse days, nobody wanted to gather in groups, least of all to embrace tearful, snotty mourners. So, we never had a funeral. I flew to California, where my dad spent his final years, and gathered with my brothers, hoping to do something symbolic, like stack stones at the beach or scream into the surf. But a Trump rally was whooping through town that day, and the sky glimmered apocalyptic-orange from wildfires. We renounced our imagined grieving rituals. Eating fish tacos in a socially distanced circle would have to suffice. But malaise had already crept in before that staggering loss. <a target="_blank" class="" href="https://www.businessinsider.com/loved-company-bored-at-work-found-dream-job-2024-3">Life had grown predictable</a> and soft, thickening around the middle like an aging waistline. Overwork had something to do with it. I'd spent carefree years bouncing around Kyrgyzstan and Lebanon, Sri Lanka and Mexico, India and Armenia. Then in my mid-30s, I wandered into a<a target="_blank" class="" href="https://www.businessinsider.com/return-to-office-hybrid-work-model-quit-jobs-2023-8"> full-time desk job</a>. "Living death," that's how my philosopher-slash-guitarist father had nicknamed <a target="_blank" class="" href="https://www.businessinsider.com/fight-return-to-office-mandates-remote-work-amazon-apple-2023-3">office work</a>. No surprises. Every day felt the same. The role itself — designing photo exhibits and documenting peace initiatives — was often fascinating, and I welcomed the reprieve from financial precarity. But sitting under fluorescent lights all day made me feel like a caged panther. Or maybe a cyborg. I wasn't prepared for<a target="_blank" class="" href="https://www.businessinsider.com/quiet-vacations-work-trends-culture-pto-travel-job-stress-2024-6"> corporate culture</a>. Months in, a colleague's mother died. "Condolences," I wrote as the subject line of an Outlook email, though I wanted to shatter our cubicle decorum and howl in vicarious despair. Then, my own dad died, and the colleague simply hit reply and added her own message of sympathy. How bleak our bloodless exchange felt. Was this how I'd spend the rest of my life, marking traumatic milestones with Microsoft Office notifications? <a target="_blank" class="" href="https://www.businessinsider.com/guides/health/mental-health/stages-of-grief">Grief was overwhelming</a>, but productivity required putting on a happy face at work. I soldiered ahead joylessly. Firing off four dozen emails a day became a grim escape — a way not to think, a way to cushion myself from new experiences, and thus further loss. To no one's surprise, burnout followed. <div type="image" title="View from hotel overlooking the Bay of Algiers" height="4000" width="6000" msid="113377531" hostid="261" sizebytes="725790"></div><h2 id="69e9182f-8a49-4e0a-b4de-77e58e9fd129">A freelance job helped me feel free again</h2>I needed to start living again. That meant salvaging parts of myself I'd jettisoned on my race to adulthood, including the itinerant writer in me. When a magazine offered me an assignment in Algeria, I jumped at the chance. This would be my first solo reporting trip in four years. Could I still navigate unfamiliar cities alone or cold-call strangers? Luckily, after a few days in Oran and Algiers, <a target="_blank" class="" href="https://www.businessinsider.com/what-muscle-memory-brain-cerebellum-2015-4">muscle memory</a> took over. In the name of research, I started hitting up red-lit clubs, where cabaret singers warbled risqué Arabic lyrics to crowds sloppy with whisky. One night, around 2 a.m., I squinted through threads of smoke at the man crooning into a mic, ears ringing violently, and thought: "This is exactly where I want to be." On the eve of my landmark birthday, contemplating my feet splayed over the tiled tub in my hotel suite, I thought about how rai singers — a form of Algerian folk music — were paragons of living boldly. Rai singers had even been assassinated for making music. I make no comparison between their incredible courage and my own infinitely milder risks, which soon included drifting back to <a target="_blank" class="" href="https://www.businessinsider.com/millennial-rto-return-workplace-quitting-job-office-trends-freelance-benefits-2023-7">freelance work</a>. But when you consider women of earlier generations, whose lives were narrowly circumscribed between marriage and motherhood, the idea of living by one's own wits starts to feel pretty radical. There's nothing wrong with wanting a more conventional path or a less messy career. But on the cusp of midlife, what I still craved was the thrill of a blank page.

'Living death' was my dad's nickname for office work. Now I'm in my 40s — and I can see why.

India reported 2,468 <keyword id="9188069" type="General" weightage="20" keywordseo="fresh-covid-cases" source="Orion">fresh Covid cases</keyword> in the last 24 hours as against 1,968 <keyword id="8869954" type="General" weightage="20" keywordseo="covid-cases" source="Orion">Covid cases</keyword> recorded on the previous day, said the Union Health Ministry on Wednesday. In the same period, the country recorded 17 more Covid related deaths, taking the national fatalities tally to 5,28,733 as per the report. The active caseload presently stands at 33,318 cases, accounting for 0.07 per cent of the country's total positive cases. The recovery of 3,731 patients in the last 24 hours took the cumulative tally to 4,40,39,883. Consequently, India's recovery rate stands at 98.74 per cent. India's daily positivity rate has been reported to be 1.32 per cent, while the weekly positivity rate currently also stands at 1.32 per cent. Also in the same period, a total of 1,87,511 tests were conducted across the country, increasing the overall tally to over 89.61 crore. As of Wednesday morning, India's Covid-19 vaccination coverage exceeded 218.83 crore. Over 4.10 crore adolescents have been administered with a first dose of Covid-19 jab since the beginning of vaccination drive for this age bracket. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/india/news/trs-meeting-underway-to-convert-itself-into-national-party/articleshow/94659091.cms" style="">TRS meeting underway to convert itself into national party</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/science/health/news/mrna-booster-immunisations-protect-against-covid-19-for-4-5-months-study/articleshow/94644964.cms" style="">mRNA booster immunisations protect against Covid-19 for 4-5 months: study</a>

India reports 2,468 fresh Covid cases, 17 deaths

<keyword id="19895063" type="General" weightage="20" keywordseo="India" source="keywords">India</keyword> has reported its first confirmed case of <keyword id="20134986" type="General" weightage="20" keywordseo="Monkeypox" source="keywords">Monkeypox</keyword> (<keyword id="20965747" type="General" weightage="20" keywordseo="Mpox" source="keywords">Mpox</keyword>) caused by the highly transmissible <keyword id="22812233" type="General" weightage="20" keywordseo="Clade-1B" source="keywords">Clade 1B</keyword> strain, marking a significant moment in the country’s ongoing battle against the <keyword id="20542503" type="General" weightage="20" keywordseo="viral-disease" source="keywords">viral disease</keyword>. According to sources in the <keyword id="19896140" type="General" weightage="20" keywordseo="Health-Ministry" source="keywords" meta.keywordsubtype="org" meta.entityname="Health Ministry" meta.hostid="261" meta.entityid="Health Ministry">Health Ministry</keyword>, this case involves a patient from <keyword id="19896018" type="General" weightage="20" keywordseo="Kerala" source="keywords">Kerala</keyword> <keyword id="19895006" type="General" weightage="20" keywordseo="WHO" source="keywords">who</keyword> had recently returned from Dubai. The World Health Organization (WHO) had recently raised concerns about the spread of Mpox, classifying it as a disease of international concern, especially as new, more infectious strains emerge. While Mpox has appeared in India before, all prior cases were linked to the less deadly Clade II strain. <h2>A new, more <keyword id="22892041" type="General" weightage="20" keywordseo="transmissible-strain" source="keywords">transmissible strain</keyword></h2>The case in Kerala is the first in India involving Clade 1B, a variant known for its higher transmission rate and increased mortality compared to previous strains. A Health Ministry official confirmed that the patient is currently in stable condition and that rigorous contact tracing efforts are underway to prevent further spread. This response follows India’s earlier experience with Mpox, where over 30 cases were recorded between 2022 and 2024, predominantly from travellers returning from African nations where the disease remains endemic. <h2>Mpox symptoms and spread</h2>Mpox manifests through typical viral symptoms, including fever, headaches, and muscle pain, eventually leading to skin rashes or lesions. These rashes often emerge a few days after the fever and vary in appearance, sometimes resembling fluid-filled blisters that crust over and heal within a few weeks. However, while symptoms usually resolve without intervention, the disease can lead to serious complications and, in rare instances, death. Unlike COVID-19 or influenza, Mpox is not airborne. Its primary mode of transmission is through close physical contact, particularly skin-to-skin contact or exposure to contaminated materials, such as bedding or clothing. Sexual transmission is also a significant factor in the spread of the disease. Health experts stress the importance of maintaining strict hygiene practices and ensuring that caregivers use personal protective equipment when attending to infected individuals. <h2>Health Ministry's preparedness</h2>In light of this new development, the Indian government is taking preventive measures to contain the situation. Union Health Secretary Apurva Chandra has issued directives to states and Union Territories, urging them to ensure isolation facilities are readily available for suspected or confirmed cases. These measures also include ramping up resources such as trained healthcare personnel and medical supplies. While there is no immediate risk of a widespread outbreak, authorities are adopting a cautious approach to avoid any potential escalation. Recent cases, such as one involving a resident of Hisar, Haryana, demonstrate the country’s ongoing efforts to monitor, isolate, and treat Mpox cases effectively. (With inputs from agencies)

More transmissible, higher fatality rate: India records first case of fast-spreading Mpox strain Clade 1B in Kerala man

The pharmaceutical giant <keyword id="19910149" type="General" weightage="20" keywordseo="AstraZeneca" source="keywords" meta.keywordsubtype="org" meta.entityname="AstraZeneca" meta.hostid="261" meta.entityid="AstraZeneca">AstraZeneca</keyword>'s <keyword id="20040659" type="General" weightage="20" keywordseo="COVID-19-vaccine" source="keywords">COVID-19 vaccine</keyword> is being withdrawn worldwide after the company acknowledged for the first time in court documents that it can cause a rare and dangerous side effect, according to a report in the British Newspaper 'The Telegraph'. AstraZeneca has announced that the <keyword id="19959412" type="General" weightage="20" keywordseo="vaccine" source="keywords">vaccine</keyword> was being removed from markets for commercial reasons. It further said that the vaccine was no longer being made or supplied, having been superseded by updated vaccines that fight new variants. The application to withdraw the vaccine was made on March 5 and came into effect on May 7. The vaccine can be no longer used in the European Union following the company's decision to withdraw its "marketing authorisation." Similar applications will be submitted in the UK and other nations in the coming months that have given a go-ahead to the vaccine, known as Vaxzevria. In recent months, Vaxzevria has come under scrutiny over a very rare side effect, which causes blood clots and low blood platelet counts. In court documents, AstraZeneca in the High Court in February admitted that the vaccine "can, in very rare cases, cause <keyword id="20218859" type="General" weightage="20" keywordseo="TTS" source="keywords">TTS</keyword>". TTS which stands for <keyword id="21475609" type="General" weightage="20" keywordseo="Thrombosis-with-Thrombocytopenia-Syndrome" source="keywords">Thrombosis with Thrombocytopenia Syndrome</keyword> has been associated with at least 81 deaths in the UK and hundreds of serious injuries. More than 50 alleged victims and grieving relatives have filed a lawsuit against AstraZeneca in a High Court case. AstraZeneca has insisted that the decision to withdraw the vaccine is not related to the case or admission that it can cause TTS and termed the timing a pure coincidence, according to The Telegraph report. "We are incredibly proud of the role Vaxzevria played in ending the global pandemic. According to independent estimates, over 6.5 million lives were saved in the first year of use alone and over three billion doses were supplied globally. Our efforts have been recognised by governments around the world and are widely regarded as being a critical component of ending the global pandemic," The Telegraph quoted AstraZeneca as saying. In a statement, the pharmaceutical giant said, "As multiple, variant Covid-19 vaccines have since been developed, there is a surplus of available updated vaccines", adding that it has led to a decline in demand for Vaxzevria, which is no longer being manufactured or supplied, The Telegraph reported. It further announced its decision to initiate the withdrawal of the marketing authorisations for Vaxzevria within Europe. The company said, "We will now work with regulators and our partners to align on a clear path forward to conclude this chapter and significant contribution to the Covid-19 pandemic." Last week, AstraZeneca reiterated its commitment to patient safety while emphasising the vaccine's overall safety profile. An AstraZeneca spokesperson had stated, "Our sympathy goes out to anyone who has lost loved ones or reported health problems. Patient safety is our highest priority, and regulatory authorities have clear and stringent standards to ensure the safe use of all medicines, including vaccines." This comes in the wake of a recent admission by AstraZeneca, the pharmaceutical company, that its <keyword id="19896627" type="General" weightage="20" keywordseo="covid" source="keywords">Covid</keyword> vaccine Covishield and Vaxzevria "can, in very rare cases, cause Thrombosis Thrombocytopenia Syndrome (TTS)." Despite these rare occurrences, the pharmaceutical company maintained that extensive clinical trial data and real-world evidence consistently support the vaccine's safety and efficacy. Regulatory agencies worldwide continue to assert that the benefits of vaccination outweigh the risks of such extremely rare side effects. SEE ALSO:<a href="https://www.businessinsider.in/stock-market/webstories/aadhar-housing-finance-ipo-price-band-to-risk-factors-all-you-need-to-know/slidelist/109919298.cms" target="_blank"></a> <a href="https://www.businessinsider.in/stock-market/webstories/aadhar-housing-finance-ipo-price-band-to-risk-factors-all-you-need-to-know/slidelist/109919298.cms" target="_blank">Aadhar Housing Finance IPO – Price band to risk factors, all you need to know</a><a href="https://www.businessinsider.in/business/auto/webstories/top-selling-cars-in-india-in-april-2024-tata-punch-continues-to-dominate/slidelist/109909744.cms" target="_blank"></a> <a href="https://www.businessinsider.in/business/auto/webstories/top-selling-cars-in-india-in-april-2024-tata-punch-continues-to-dominate/slidelist/109909744.cms" target="_blank">Top-selling cars in India in April 2024 – Tata Punch continues to dominate</a><a href="https://www.businessinsider.in/tech/news/worldwide-tablet-shipments-grow-in-q1-2024-after-two-years-of-decline/articleshow/109876390.cms" target="_blank"></a> <a href="https://www.businessinsider.in/tech/news/worldwide-tablet-shipments-grow-in-q1-2024-after-two-years-of-decline/articleshow/109876390.cms" target="_blank">Worldwide tablet shipments grow in Q1 2024 after two years of decline</a>

You Searched For "covid death india" and got 5 results

AstraZeneca continues to face legal action even after withdrawing its COVID vaccine! Know all about it here

Kunal Kambli

'Living death' was my dad's nickname for office work. Now I'm in my 40s — and I can see why.

Ariel Sophia Bardi

India reports 2,468 fresh Covid cases, 17 deaths

IANS

More transmissible, higher fatality rate: India records first case of fast-spreading Mpox strain Clade 1B in Kerala man

BI India Bureau

AstraZeneca withdraws COVID-19 vaccine worldwide, cites commercial reasons

ANI

Popular Keywords

Buying Guides